Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Activated Factor VII (rFVIIa/ NovoSeven®) in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

Trial Profile

Recombinant Activated Factor VII (rFVIIa/ NovoSeven®) in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Haemorrhage; Thrombocytopenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Oct 2018 Status changed from recruiting to completed.
    • 23 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 23 Aug 2017 Planned initiation date changed from 17 Aug 2017 to 21 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top